Could a psoriasis drug help thickened hands and feet?
NCT ID NCT06561321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily cream called tapinarof, already used for psoriasis, in 6 adults with palmoplantar keratoderma — a condition that causes painful thickening of skin on the palms and soles. Researchers want to see if the cream can clear or improve the skin and check for side effects. It's a small, early-phase trial at Indiana University.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tapinarof cream
- What this could lead to
- If it works, this could point toward a new topical treatment for palmoplantar keratoderma, a rare skin condition with limited options.
- What could go wrong
- This is a very small early-phase trial with only 6 participants, so results may not apply to everyone. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 6 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ability to discern and provide written informed consent and voluntarily adhere to all of the protocol requirements * Male or female subjects in their adult years (≥ 18 years of age), inclusive, from the time of providing written subject-investigator agreement. * Confirmed clinical diagnosis of palmoplantar keratoderma. Exclusion Criteria: * Treatment with any of the following medications and therapies during the duration of the study\*: * Topical corticosteroids * Keratolytic agents (eg, 6% salicylic acid, 70% propylene glycol, 30% water) * Topical retinoids * Topical vitamin D ointment (calcipotriol) * Oral retinoids (acitretin) * If on any of these then a washout period of at least 2 weeks will be enforced before the study begins. This washout period is meant to ensure that any effects or residues from previous treatments are minimized before starting the study. * Prior exposure to Tapinarof treatment * Known history or suspicion of hypersensitivity reactions, or contraindications to any or all components of the drug or drugs of similar properties. * Currently participating in another clinical study for the same purpose. * Potential or confirmed pregnancy: Individuals who are currently pregnant or have confirmed pregnancy at the time of screening will be excluded from participation in the study. This criterion aims to ensure the safety of participants and adhere to ethical considerations regarding the potential risks associated with the study interventions during pregnancy. * Any other factors specifically not listed above but deemed patient unsuitable by the discretion of the investigators.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Palmoplantar keratoderma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Department of Dermatology
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.